Intensity Therapeutics, Inc. (INTS) Stock

About Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc. is led by CEO Lewis H. Bender, publicly traded since 2023.

Intensity Therapeutics, Inc. (INTS) stock trades at $3.25 with a market capitalization of $8.78M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.71, reflecting a net loss over the last twelve months, price-to-book of 1.01, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.12 and $43.50, and currently trades 92.5% below its 52-week high.

On profitability, Intensity Therapeutics, Inc. generates a return on equity (ROE) of -116.61% (negative, reflecting a net loss), return on capital employed of -123.79%.

Intensity Therapeutics, Inc. by the numbers, 2019–2025

Between 2019 and 2025 Intensity Therapeutics, Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-12.0M.

On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-11.0M.

Borrowings stand at $0, cash from operations was $-9.0M in the latest year, positive in 0 of the last 7.

Return on equity has averaged -115.2% over five years, and was -100.0% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Intensity Therapeutics, Inc. (INTS) — frequently asked questions